Molecular Targets of Resveratrol in Carcinogenesis

  • Seung J. Baek
  • Nichelle C. Whitlock
Part of the Evidence-based Anticancer Complementary and Alternative Medicine book series (ACAM)


Resveratrol, a dietary phytoalexin readily available in the diet, is reported to possess antitumorigenic and anti-inflammation activity in several cancers. However, the molecular mechanisms and/or targets underlying the antitumorigenic activity of this compound remain largely unknown. As a potential signaling pathway modulator, resveratrol is shown to affect a multitude of signaling transduction pathways, and it is likely that this collective activity may play an important role in resveratrol-induced antitumorigenesis. Therefore, the elucidation of molecular targets of resveratrol is necessary to understand how this compound is beneficial in antitumorigenic processes. Studies to identify molecular markers have recently spawned increasing examination of the possible targets of resveratrol as related to anticancer proteins. These include, but are not limited to: (1) inhibition of carcinogenic activation and induction of detoxification by Phase I and Phase II xenobiotic metabolizing enzymes, respectively, (2) modulation of cell survival and apoptosis, (3) suppression of pro-inflammatory signaling pathways, (4) inhibition of angiogenesis, invasion, and metastasis, and (5) modulation of hormonal receptors. This chapter summarizes the diverse molecular targets of resveratrol in prevention and treatment of carcinogenesis.


Dextran Sodium Sulfate Aryl Hydrocarbon Receptor Cigarette Smoke Extract Endometrial Cancer Cell Resveratrol Treatment 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Androutsopoulos, V., Tsatsakis, A., & Spandidos, D. (2009). Cytochrome P450 CYP1A1: Wider roles in cancer progression and prevention. BMC Cancer, 9, 187.PubMedGoogle Scholar
  2. Artandi, S. E., & DePinho, R. A. (2010). Telomeres and telomerase in cancer. Carcinogenesis, 31, 9–18.PubMedGoogle Scholar
  3. Athar, M., Back, J. H., Tang, X., et al. (2007). Resveratrol: A review of preclinical studies for human cancer prevention. Toxicology and applied pharmacology, 224(3), 274–283.PubMedGoogle Scholar
  4. Auyeung, K., & Ko, J. (2009). Coptis chinensis inhibits hepatocellular carcinoma cell growth through nonsteroidal anti-inflammatory drug-activated gene activation. International Journal of Molecular Medicine, 24, 571–577.PubMedGoogle Scholar
  5. Auyeung, K., & Ko, J. (2010). Novel herbal flavonoids promote apoptosis but differentially induce cell cycle arrest in human colon cancer cell. Investigational New Drugs, 28, 1–13.PubMedGoogle Scholar
  6. Auyeung, K. K., Cho, C. H., & Ko, J. K. (2009). A novel anticancer effect of Astragalus saponins: Transcriptional activation of NSAID-activated gene. International Journal of Cancer, 125, 1082–1091.Google Scholar
  7. Baek, S. J., Kim, K. S., Nixon, J. B., et al. (2001). Cyclooxygenase inhibitors regulate the expression of a TGF-β superfamily member that has proapoptotic and antitumorigenic activities. Molecular Pharmacology, 59, 901–908.PubMedGoogle Scholar
  8. Baek, S. J., & Wilson, L. C., & Eling, T. E. (2002). Resveratrol enhances the expression of non-steroidal anti-inflammatory drug-activated gene (NAG-1) by increasing the expression of p53. Carcinogenesis, 23, 425–432.PubMedGoogle Scholar
  9. Baek, S. J., Kim, J. S., Jackson, F. R., et al. (2004). Epicatechin gallate-induced expression of NAG-1 is associated with growth inhibition and apoptosis in colon cancer cells. Carcinogenesis, 25, 2425–2432.PubMedGoogle Scholar
  10. Baek, S. J., Okazaki, R., Lee, S. -H., et al. (2006). Nonsteroidal anti-inflammatory drug-activated gene-1 over expression in transgenic mice suppresses intestinal neoplasia. Gastroenterology, 131, 1553–1560.PubMedGoogle Scholar
  11. Bai, Y., Mao, Q. Q., Qin, J., et al. (2010). Resveratrol induces apoptosis and cell cycle arrest of human T24 bladder cancer cells in vitro and inhibits tumor growth in vivo. Cancer Science, 101, 488–493.PubMedGoogle Scholar
  12. Balkwill, F., & Mantovani, A. (2010). Cancer and inflammation: Implications for pharmacology and therapeutics. Clinical Pharmacology and Therapeutics, 87, 401–406.PubMedGoogle Scholar
  13. Banerjee, S., Bueso-Ramos, C., & Aggarwal, B. B. (2002). Suppression of 7,12-dimethylbenz(a)anthracene-induced mammary carcinogenesis in rats by resveratrol. Cancer Research, 62, 4945–4954.PubMedGoogle Scholar
  14. Baur, J. A., & Sinclair, D. A. (2006). Therapeutic potential of resveratrol: The in vivo evidence. Nature Reviews Drug Discovery, 5, 493–506.PubMedGoogle Scholar
  15. Beedanagari, S. R., Bebenek, I., Bui, P., et al. (2009). Resveratrol inhibits dioxin-induced expression of human CYP1A1 and CYP1B1 by inhibiting recruitment of the aryl hydrocarbon receptor complex and RNA polymerase II to the regulatory regions of the corresponding genes. Toxicological Sciences, 110, 61–67.PubMedGoogle Scholar
  16. Benitez, D. A., Pozo-Guisado, E., Alvarez-Barrientos, A., et al. (2007). Mechanisms involved in resveratrol-induced apoptosis and cell cycle arrest in prostate cancer-derived cell lines. Journal of Andrology, 28, 282–293.PubMedGoogle Scholar
  17. Berge, G., Ovrebo, S., Botnen, I. V., et al. (2004). Resveratrol inhibits benzo[a]pyrene-DNA adduct formation in human bronchial epithelial cells. British Journal of Cancer, 91, 333–338.PubMedGoogle Scholar
  18. Bhardwaj, A., Sethi, G., Vadhan-Raj, S., et al. (2007). Resveratrol inhibits proliferation, induces apoptosis, overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-κB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells. Blood, 109, 2293–2302.PubMedGoogle Scholar
  19. Bhat, K. P. L., & Pezzuto, J. M. (2001). Resveratrol exhibits cytostatic and antiestrogenic properties with human endometrial adenocarcinoma (Ishikawa) cells. Cancer Research, 61, 6137–6144.PubMedGoogle Scholar
  20. Bhat, K. P. L., Lantvit, D., Christov, K., et al. (2001). Estrogenic and antiestrogenic properties of resveratrol in mammary tumor models. Cancer Research, 61, 7456–7463.PubMedGoogle Scholar
  21. Binet, R., Ythier, D., Robles, A. I., et al. (2009). WNT16B is a new marker of cellular senescence that regulates p53 activity and the phosphoinositide 3-kinase/Akt pathway. Cancer Research, 69, 9183–9191.PubMedGoogle Scholar
  22. Bishayee, A. (2009). Cancer prevention and treatment with resveratrol: From rodent studies to clinical trials. Cancer Prevention Research, 2, 409–418.PubMedGoogle Scholar
  23. Bishayee, A., & Dhir, N. (2009). Resveratrol-mediated chemoprevention of diethylnitrosamine-initiated hepatocarcinogenesis: Inhibition of cell proliferation and induction of apoptosis. Chemico Biological Interactions, 179, 131–144.PubMedGoogle Scholar
  24. Bishayee, A., Barnes, K. F., Bhatia, D., et al. (2010a). Resveratrol suppresses oxidative stress and inflammatory response in diethylnitrosamine-initiated rat hepatocarcinogenesis. Cancer Prevention Research, 3, 753–763.Google Scholar
  25. Bishayee, A., Waghray, A., Barnes, K., et al. (2010b). Suppression of the inflammatory cascade is implicated in resveratrol chemoprevention of experimental hepatocarcinogenesis. Pharmaceutical Research, 27, 1080–1091.Google Scholar
  26. Boocock, D. J., Faust, G. E. S., Patel, K. R., et al. (2007). Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiology, Biomarkers & Prevention, 16, 1246–1252.Google Scholar
  27. Bottone, F. G., Moon, Y., Kim, J. S., et al. (2005). The anti-invasive activity of cyclooxygenase inhibitors is regulated by the transcription factor ATF3 (activating transcription factor 3). Molecular Cancer Therapeutics, 4, 693–703.PubMedGoogle Scholar
  28. Bowers, J. L., Tyulmenkov, V. V., Jernigan, S. C., et al. (2000). Resveratrol Acts as a Mixed Agonist/Antagonist for Estrogen Receptors α and β. Endocrinology, 141, 3657–3667.PubMedGoogle Scholar
  29. Brown, J. M., & Attardi, L. D. (2005). The role of apoptosis in cancer development and treatment response. Nature Reviews Cancer, 5, 231–237.PubMedGoogle Scholar
  30. Calamini, B., Ratia, K., Malkowski, M. G., et al. (2010). Pleiotropic mechanisms facilitated by resveratrol and its metabolites. The Biochemical Journal, 429, 273–282.PubMedGoogle Scholar
  31. Cao, Z., Fang, J., Xia, C., et al. (2004). Trans-3,4,5′-trihydroxystibene inhibits hypoxia-inducible factor 1α and vascular endothelial growth factor expression in human ovarian cancer cells. Clinical Cancer Research, 10, 5253–5263.PubMedGoogle Scholar
  32. Castello, L., & Tessitore, L. (2005). Resveratrol inhibits cell cycle progression in U937 cells. Oncology Reports, 13, 133–137.PubMedGoogle Scholar
  33. Chan, W. K., & Delucchi, A. B. (2000). Resveratrol, a red wine constituent, is a mechanism-based inactivator of cytochrome P450 3A4. Life Sciences, 67, 3103–3112.PubMedGoogle Scholar
  34. Corre, L. L., Chalabi, N., Delort, L., et al. (2005). Resveratrol and breast cancer chemoprevention: Molecular mechanisms. Molecular Nutrition & Food Research, 49, 462–471.Google Scholar
  35. Cui, X., Jin, Y., & Hofseth, A. B., et al. (2010). Resveratrol suppresses colitis and colon cancer associated with colitis. Cancer Prevention Research, 3, 549–559.PubMedGoogle Scholar
  36. Danese, S., & Mantovani, A. (2010). Inflammatory bowel disease and intestinal cancer: A paradigm of the Yin-Yang interplay between inflammation and cancer. Oncogene, 29, 3313–3323.PubMedGoogle Scholar
  37. Dann, J. M., Sykes, P. H., Mason, D. R., et al. (2009). Regulation of vascular endothelial growth factor in endometrial tumour cells by resveratrol and EGCG. Gynecologic Oncology, 113, 374–378.PubMedGoogle Scholar
  38. Degrassi, F., Fiore, M., & Palitti, F. (2004). Chromosomal aberrations and genomic instability induced by topoisomerase- targeted antitumour drugs. Current Medicinal Chemistry Anti Cancer, 4, 317–325.Google Scholar
  39. Delmas, D., Rébé, C., Micheau, O., et al. (2004). Redistribution of CD95, DR4 and DR5 in rafts accounts for the synergistic toxicity of resveratrol and death receptor ligands in colon carcinoma cells. Oncogene, 23, 8979–8986.PubMedGoogle Scholar
  40. Dennis, T., Fanous, M., & Mousa, S. (2009). Natural products for chemopreventive and adjunctive therapy in oncologic disease. Nutrition and Cancer, 61, 587–597.PubMedGoogle Scholar
  41. Du, L., Neis, M. M., Ladd, P. A., et al. (2006). Differentiation-specific factors modulate epidermal CYP1–4 gene expression in human skin in response to retinoic acid and classic aryl hydrocarbon receptor ligands. The Journal of Pharmacology and Experimental Therapeutics, 319, 1162–1171.PubMedGoogle Scholar
  42. Duffy, M., McGowan, P., & Gallagher, W. (2008). Cancer invasion and metastasis: Changing views. The Journal of Pathology, 214, 283–293.PubMedGoogle Scholar
  43. El-Mowafy, A. M., & Alkhalaf, M. (2003). Resveratrol activates adenylyl-cyclase in human breast cancer cells: A novel, estrogen receptor-independent cytostatic mechanism. Carcinogenesis, 24, 869–873.PubMedGoogle Scholar
  44. Estrov, Z., Shishodia, S., Faderl, S., et al. (2003). Resveratrol blocks interleukin-1β-induced activation of the nuclear transcription factor NF-κB, inhibits proliferation, causes S-phase arrest, induces apoptosis of acute myeloid leukemia cells. Blood, 102, 987–995.PubMedGoogle Scholar
  45. Fan, E., Jiang, S., Zhang, L., et al. (2008). Molecular mechanism of apoptosis induction by resveratrol, a natural cancer chemopreventive agent. International Journal for Vitamin and Nutrition Research, 78, 3–8.PubMedGoogle Scholar
  46. Fan, F., Jin, S., Amundson, S. A., et al. (2002). ATF3 induction following DNA damage is regulated by distinct signaling pathways and over-expression of ATF3 protein suppresses cells growth. Oncogene, 21, 7488–7496.PubMedGoogle Scholar
  47. Farnebo, M., Bykov, V. J. N., & Wiman, K. G. (2010). The p53 tumor suppressor: A master regulator of diverse cellular processes and therapeutic target in cancer. Biochemical and Biophysical Research Communications, 396, 85–89.PubMedGoogle Scholar
  48. Fuggetta, M. P., Lanzilli, G., Tricarico, M., et al. (2006). Effects of resveratrol on proliferation and telomerase activity of human colon cancer cells in vitro. Journal of Experimental & Clinical Cancer Research, 25, 189–193.Google Scholar
  49. Gallmeier, E., Calhoun, E. S., Rago, C., et al. (2006). Targeted disruption of FANCC and FANCG in human cancer provides a preclinical model for specific therapeutic options. Gastroenterology, 130, 2145–2154.PubMedGoogle Scholar
  50. Garg, A. K., Buchholz, T. A., & Aggarwal, B. B. (2005). Chemosensitization and radiosensitization of tumors by plant polyphenols. Antioxidants & Redox Signaling, 7, 1630–1647.Google Scholar
  51. Gatouillat, G., Balasse, E., Joseph-Pietras, D., et al. (2010). Resveratrol induces cell-cycle disruption and apoptosis in chemoresistant B16 melanoma. Journal of Cellular Biochemistry, 110, 893–902.PubMedGoogle Scholar
  52. Gehm, B. D., McAndrews, J. M., Chien, P. Y., et al. (1997). Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. Proceedings of the National Academy of Sciences of the United States of America, 94, 14138–14143.PubMedGoogle Scholar
  53. Gehm, B. D., Levenson, A. S., Liu, H., et al. (2004). Estrogenic effects of resveratrol in breast cancer cells expressing mutant and wild-type estrogen receptors: Role of AF-1 and AF-2. The Journal of Steroid Biochemistry and Molecular Biology, 88, 223–234.PubMedGoogle Scholar
  54. Ghobrial, I. M., Witzig, T. E., & Adjei, A. A. (2005). Targeting apoptosis pathways in cancer therapy. CA: A Cancer Journal for Clinicians, 55, 178–194.Google Scholar
  55. Golkar, L., Ding, X. Z., Ujiki, M. B., et al. (2007). Resveratrol inhibits pancreatic cancer cell proliferation through transcriptional induction of macrophage inhibitory cytokine-1. The Journal of Surgical Research, 138, 163–169.PubMedGoogle Scholar
  56. Harikumar, K. B., & Aggarwal, B. (2008). Resveratrol: A multitargeted agent for age-associated chronic diseases. Cell Cycle, 7, 1020–1035.PubMedGoogle Scholar
  57. Harikumar, K. B., Kunnumakkara, A. B., Sethi, G., et al. (2010). Resveratrol, a multitargeted agent, can enhance antitumor activity of gemcitabine in vitro and in orthotopic mouse model of human pancreatic cancer. International Journal of Cancer, 127, 257–268.Google Scholar
  58. Heiss, E. H., Schilder, Y. D. C., & Dirsch, V. M. (2007). Chronic treatment with resveratrol induces redox stress- and ataxia telangiectasia-mutated (ATM)-dependent senescence in p53-positive cancer cells. The Journal of Biological Chemistry, 282, 26759–26766.PubMedGoogle Scholar
  59. Hsieh, T., & Wu, J. (2008). Suppression of cell proliferation and gene expression by combinatorial synergy of EGCG, resveratrol and gamma-tocotrienol in estrogen receptor-positive MCF-7 breast cancer cells. International Journal of Cancer, 33, 851–859.Google Scholar
  60. Huang, X., Li, X., & Guo, B. (2008). KLF6 Induces Apoptosis in Prostate Cancer Cells through Up-regulation of ATF3. The Journal of Biological Chemistry, 283, 29795–29801.PubMedGoogle Scholar
  61. Hudson, T. S., Hartle, D. K., Hursting, S. D., et al. (2007). Inhibition of prostate cancer growth by muscadine grape skin extract and resveratrol through distinct mechanisms. Cancer Research, 67, 8396–8405.PubMedGoogle Scholar
  62. Jana, S., & Mandlekar, S. (2009). Role of Phase II drug metabolizing enzymes in cancer chemoprevention. Current Drug Metabolism, 10, 595–616.PubMedGoogle Scholar
  63. Jang, M., Cai, L., Udeani, G. O., et al. (1997). Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science, 275, 218–220.PubMedGoogle Scholar
  64. Jazirehi, A. R., & Bonavida, B. (2004). Resveratrol modifies the expression of apoptotic regulatory proteins and sensitizes non-Hodgkin’s lymphoma and multiple myeloma cell lines to paclitaxel-induced apoptosis. Molecular Cancer Therapeutics, 3, 71–84.PubMedGoogle Scholar
  65. Jiang, H., Zhang, L., Kuo, J., et al. (2005). Resveratrol-induced apoptotic death in human U251 glioma cells. Molecular Cancer Therapeutics, 4, 554–561.PubMedGoogle Scholar
  66. Joe, A. K., Liu, H., Suzui, M., et al. (2002). Resveratrol induces growth inhibition, s-phase arrest, apoptosis, changes in biomarker expression in several human cancer cell lines. Clinical Cancer Research, 8, 893–903.PubMedGoogle Scholar
  67. John, A., & Tuszynski, G. (2001). The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis. Pathology Oncology Research, 7, 14–23.PubMedGoogle Scholar
  68. Kachnic, L. A., Li, L., Fournier, L., et al. (2010). Fanconi Anemia pathway heterogeneity revealed by cisplatin and oxaliplatin treatments. Cancer Letters, 292, 73–79.PubMedGoogle Scholar
  69. Kai, L., Samuel, S. K., & Levenson, A. S. (2010). Resveratrol enhances p53 acetylation and apoptosis in prostate cancer by inhibiting MTA1/NuRD complex. International Journal of Cancer, 126, 1538–1548.Google Scholar
  70. Kensler, T. W., & Wakabayashi, N. (2010). Nrf2: Friend or foe for chemoprevention? Carcinogenesis, 31, 90–99.PubMedGoogle Scholar
  71. Kessenbrock, K., Plaks, V., & Werb, Z. (2010). Matrix metalloproteinases: Regulators of the tumor microenvironment. Cell, 141, 52–67.PubMedGoogle Scholar
  72. Kim, A. L., Zhu, Y., Zhu, H., et al. (2006). Resveratrol inhibits proliferation of human epidermoid carcinoma A431 cells by modulating MEK1 and AP-1 signalling pathways. Experimental Dermatology, 15, 538–546.PubMedGoogle Scholar
  73. Kim, D. S., Kwon, H. M., Choi, J. S., et al. (2007). Resveratrol blunts tumor necrosis factor-α-induced monocyte adhesion and transmigration. Nutrition Research and Practice, 1, 285–290.PubMedGoogle Scholar
  74. Kim, K. -S., Baek, S. J., & Flake, G. P., et al. (2002). Expression and regulation of nonsteroidal anti-inflammatory drug-activated gene (NAG-1) in human and mouse tissue. Gastroenterology, 122, 1388–1398.PubMedGoogle Scholar
  75. Kode, A., Rajendrasozhan, S., Caito, S., et al. (2008). Resveratrol induces glutathione synthesis by activation of Nrf2 and protects against cigarette smoke-mediated oxidative stress in human lung epithelial cells. American Journal of Physiology Lung Cellular and Molecular Physiology, 294, L478–L488.PubMedGoogle Scholar
  76. Koh, M., Spivak-Kroizman, T., & Powis, G. (2010). HIF-1alpha and cancer therapy. Recent Results in Cancer Research, 180, 15–34.PubMedGoogle Scholar
  77. Kowalczyk, M. C., Walaszek, Z., Kowalczyk, P., et al. (2009). Differential effects of several phytochemicals and their derivatives on murine keratinocytes in vitro and in vivo: Implications for skin cancer prevention. Carcinogenesis, 30, 1008–1015.PubMedGoogle Scholar
  78. Kubota, T., Uemura, Y., Kobayashi, M., et al. (2003). Combined effects of resveratrol and paclitaxel on lung cancer cells. Anticancer Research, 23, 4039–4046.PubMedGoogle Scholar
  79. Kundu, J. K., & Surh, Y. J. (2008). Cancer chemopreventive and therapeutic potential of resveratrol: Mechanistic perspectives. Cancer Letters, 269, 243–261.PubMedGoogle Scholar
  80. Kundu, J. K., Shin, Y. K., Kim, S. H., et al. (2006). Resveratrol inhibits phorbol ester-induced expression of COX-2 and activation of NF-κB in mouse skin by blocking IκB kinase activity. Carcinogenesis, 27, 1465–1474.PubMedGoogle Scholar
  81. Kuo, P. L., Chiang, L. C., & Lin, C. C. (2002). Resveratrol-induced apoptosis is mediated by p53-dependent pathway in Hep G2 cells. Life Sciences, 72, 23–34.PubMedGoogle Scholar
  82. Lanzilli, G., Fuggetta, M. P, Tricarico, M., et al. (2006). Resveratrol down-regulates the growth and telomerase activity of breast cancer cells in vitro. International Journal of Oncology, 28, 641–648.PubMedGoogle Scholar
  83. Lee, J. E., & Safe, S. (2001). Involvement of a post-transcriptional mechanism in the inhibition of CYP1A1 expression by resveratrol in breast cancer cells. Biochemical Pharmacology, 62, 1113–1124.PubMedGoogle Scholar
  84. Lee, S. H., Kim, J. S., Yamaguchi, K., et al. (2005). Indole-3-carbinol and 3,3′-diindolylmethane induce expression of NAG-1 in a p53-independent manner. Biochemical and Biophysical Research Communications, 328, 63–69.PubMedGoogle Scholar
  85. Lee, S. H., Yamaguchi, K., Kim, J. S., et al. (2006). Conjugated linoleic acid stimulates an anti-tumorigenic protein NAG-1 in an isomer specific manner. Carcinogenesis, 27, 972–981.PubMedGoogle Scholar
  86. Lee, S. H., Cekanova, M., & Baek, S. J. (2008). Multiple mechanisms are involved in 6-gingerol-induced cell growth arrest and apoptosis in human colorectal cancer cells. Molecular Carcinogenesis, 47, 197–208.PubMedGoogle Scholar
  87. Lee, S. H., Krisanapun, C., & Baek, S. J. (2010). NSAID-activated gene-1 as a molecular target for capsaicin-induced apoptosis through a novel molecular mechanism involving GSK3β, C/EBPβ and ATF3. Carcinogenesis, 31, 719–728.PubMedGoogle Scholar
  88. Leiro, J. M., Varela, M., Piazzon, M. C., et al. (2010). The anti-inflammatory activity of the polyphenol resveratrol may be partially related to inhibition of tumour necrosis factor-α (TNF-α) pre-mRNA splicing. Molecular Immunology, 47, 1114–1120.PubMedGoogle Scholar
  89. Leone, S., Cornetta, T., Basso, E., et al. (2010). Resveratrol induces DNA double-strand breaks through human topoisomerase II interaction. Cancer Letters, 295, 167–172.PubMedGoogle Scholar
  90. Leung, H. Y., Yung, L. H., Shi, G., et al. (2009). The red wine polyphenol resveratrol reduces polycyclic aromatic hydrocarbon-induced DNA damage in MCF-10A cells. The British Journal of Nutrition, 102, 1462–1468.PubMedGoogle Scholar
  91. Li, P., Wong, J., Ayed, A., et al. (2000). Placental transforming growth factor-beta is a downstream mediator of the growth arrest and apoptotic response of tumor cells to DNA damage and p53 overexpression. The Journal of Biological Chemistry, 275, 20127–20135.PubMedGoogle Scholar
  92. Liu, B. Q., Gao, Y. Y., Niu, X. F., et al. (2010a). Implication of unfolded protein response in resveratrol-induced inhibition of K562 cell proliferation. Biochemical and Biophysical Research Communications, 391, 778–782.Google Scholar
  93. Liu, P. L., Tsai, J. R., Charles, A. L., et al. (2010b). Resveratrol inhibits human lung adenocarcinoma cell metastasis by suppressing heme oxygenase 1-mediated nuclear factor-kappaB pathway and subsequently downregulating expression of matrix metalloproteinases. Molecular Nutrition & Food Research, 54, S196–S204.Google Scholar
  94. Liu, T., Bauskin, A. R., Zaunders, J., et al. (2003). Macrophage inhibitory cytokine 1 reduces cell adhesion and induces apoptosis in prostate cancer cells. Cancer Research, 63, 5034–5040.PubMedGoogle Scholar
  95. Lu, D., Wolfgang, C., & Hai, T. (2006). Activating transcription factor 3, a stress-inducible gene, suppresses Ras-stimulated tumorigenesis. The Journal of Biological Chemistry, 281, 10473–10481.PubMedGoogle Scholar
  96. Lu, D., Chen, J., & Hai, T. (2007). The regulation of ATF3 gene expression by mitogen-activated protein kinases. The Biochemical Journal, 401, 559–567.PubMedGoogle Scholar
  97. Lu, F., Zahid, M., Wang, C., et al. (2008). Resveratrol prevents estrogen-DNA adduct formation and neoplastic transformation in MCF-10F cells. Cancer Prevention Research, 1, 135–145.PubMedGoogle Scholar
  98. Madan, E., Prasad, S., Roy, P., et al. (2008). Regulation of apoptosis by resveratrol through JAK/STAT and mitochondria mediated pathway in human epidermoid carcinoma A431 cells. Biochemical and Biophysical Research Communications, 377, 1232–1237.PubMedGoogle Scholar
  99. Mashima, T., Udagawa, S., & Tsuruo, T. (2001). Involvement of transcriptional repressor ATF3 in acceleration of caspase protease activation during DNA damaging agent-induced apoptosis. Journal of Cellular Physiology, 188, 352–358.PubMedGoogle Scholar
  100. Meeran, S. M., & Katiyar, S. K. (2008). Cell cycle control as a basis for cancer chemoprevention through dietary agents. Frontiers in Bioscience, 13, 2192–2202.Google Scholar
  101. Mikstacka, R., Baer-Dubowska, W., Wieczorek, M., et al. (2008). Thiomethylstilbenes as inhibitors of CYP1A1, CYP1A2 and CYP1B1 activities. Molecular Nutrition & Food Research, 52, S77–S83.Google Scholar
  102. Narita, M., Murata, T., Shimizu, K., et al. (2007). A role for cyclic nucleotide phosphodiesterase 4 in regulation of the growth of human malignant melanoma cells. Oncology Reports, 17, 1133–1139.PubMedGoogle Scholar
  103. Nebert, D. W., & Dalton, T. P. (2006). The role of cytochrome P450 enzymes in endogenous signalling pathways and environmental carcinogenesis. Nature Reviews Cancer, 6, 947–960.PubMedGoogle Scholar
  104. Opipari, A. W. Jr., Tan, L., Boitano, A. E., et al. (2004). Resveratrol-induced autophagocytosis in ovarian cancer cells. Cancer Research, 64, 696–703.PubMedGoogle Scholar
  105. Oyadomari, S., & Mori, M. (2003). Roles of CHOP//GADD153 in endoplasmic reticulum stress. Cell Death and Differentiation, 11, 381–389.Google Scholar
  106. Palagyi, A., Neveling, K., Plinninger, U., et al. (2010). Genetic inactivation of the Fanconi anemia gene FANCC identified in the hepatocellular carcinoma cell line HuH-7 confers sensitivity towards DNA-interstrand crosslinking agents. Molecular Cancer, 9, 127.PubMedGoogle Scholar
  107. Palsamy, P., & Subramanian, S. (2010). Ameliorative potential of resveratrol on proinflammatory cytokines, hyperglycemia mediated oxidative stress, pancreatic beta-cell dysfunction in streptozotocin-nicotinamide-induced diabetic rats. Journal of Cellular Physiology, 224, 423–432.PubMedGoogle Scholar
  108. Parekh, P., Motiwale, L., Naik, N., et al. (2010). Downregulation of cyclin D1 is associated with decreased levels of p38 MAP kinases, Akt/PKB and Pak1 during chemopreventive effects of resveratrol in liver cancer cells. Experimental and Toxicologic Pathology, 63, 167–173.PubMedGoogle Scholar
  109. Park, S. Y., Jeong, K. J., Lee, J., et al. (2007). Hypoxia enhances LPA-induced HIF-1α and VEGF expression: Their inhibition by resveratrol. Cancer Letters, 258, 63–69.PubMedGoogle Scholar
  110. Peng, T. -L., Chen, J., Mao, W., et al. (2009). Aryl hydrocarbon receptor pathway activation enhances gastric cancer cell invasiveness likely through a c-Jun-dependent induction of matrix metalloproteinase-9. BMC Cell Biology, 10, 27.PubMedGoogle Scholar
  111. Piyanuch, R., Sukhthankar, M., Wandee, G., et al. (2007). Berberine, a natural isoquinoline alkaloid, induces NAG-1 and ATF3 expression in human colorectal cancer cells. Cancer Letters, 258, 230–240.PubMedGoogle Scholar
  112. Pozo-Guisado, E., Alvarez-Barrientos, A., Mulero-Navarro, S., et al. (2002). The antiproliferative activity of resveratrol results in apoptosis in MCF-7 but not in MDA-MB-231 human breast cancer cells: Cell-specific alteration of the cell cycle. Biochemical Pharmacology, 64, 1375–1386.PubMedGoogle Scholar
  113. Pozo-Guisado, E., Lorenzo-Benayas, M. J., & Fernández-Salguero, P. M. (2004). Resveratrol modulates the phosphoinositide 3-kinase pathway through an estrogen receptor alpha-dependent mechanism: Relevance in cell proliferation. International Journal of Cancer, 109, 167–173.Google Scholar
  114. Reagan-Shaw, S., Afaq, F., Aziz, M. H., et al. (2004). Modulations of critical cell cycle regulatory events during chemoprevention of ultraviolet B-mediated responses by resveratrol in SKH-1 hairless mouse skin. Oncogene, 23, 5151–5160.PubMedGoogle Scholar
  115. Reis-Sobreiro, M., Gajate, C., & Mollinedo, F. (2009). Involvement of mitochondria and recruitment of Fas/CD95 signaling in lipid rafts in resveratrol-mediated antimyeloma and antileukemia actions. Oncogene, 28, 3221–3234.PubMedGoogle Scholar
  116. Revel, A., Raanani, H., Younglai, E., et al. (2003). Resveratrol, a natural aryl hydrocarbon receptor antagonist, protects lung from DNA damage and apoptosis caused by benzo[a]pyrene. Journal of Applied Toxicology, 23, 255–261.PubMedGoogle Scholar
  117. Roy, P., Kalra, N., Prasad, S., et al. (2009). Chemopreventive potential of resveratrol in mouse skin tumors through regulation of mitochondrial and PI3K/Akt signaling pathways. Pharmaceutical Research, 26, 211–217.PubMedGoogle Scholar
  118. Rubiolo, J. A., Mithieux, G., & Vega. F. V. (2008). Resveratrol protects primary rat hepatocytes against oxidative stress damage: Activation of the Nrf2 transcription factor and augmented activities of antioxidant enzymes. European Journal of Pharmacology, 591, 66–72.PubMedGoogle Scholar
  119. Rusin, M., Zajkowicz, A., & Butkiewicz, D. (2009). Resveratrol induces senescence-like growth inhibition of U-2 OS cells associated with the instability of telomeric DNA and upregulation of BRCA1. Mechanisms of Ageing and Development, 130, 528–537.PubMedGoogle Scholar
  120. Sánchez-Fidalgo, S., Cárdeno, A., Villegas, I., et al. (2010). Dietary supplementation of resveratrol attenuates chronic colonic inflammation in mice. European Journal of Pharmacology, 633, 78–84.PubMedGoogle Scholar
  121. Shankar, S., Chen, Q., Siddiqui, I., et al. (2007a). Sensitization of TRAIL-resistant LNCaP cells by resveratrol (3, 4′, 5 tri-hydroxystilbene): Molecular mechanisms and therapeutic potential. Journal of Molecular Signaling, 2, 7.Google Scholar
  122. Shankar, S., Siddiqui, I., & Srivastava, R. (2007b). Molecular mechanisms of resveratrol (3,4,5-trihydroxy-trans-stilbene) and its interaction with TNF-related apoptosis inducing ligand (TRAIL) in androgen-insensitive prostate cancer cells. Molecular and Cellular Biochemistry, 304, 273–285.Google Scholar
  123. Shin, D. Y., Kim, G. Y., Li, W., et al. (2009). Implication of intracellular ROS formation, caspase-3 activation and Egr-1 induction in platycodon D-induced apoptosis of U937 human leukemia cells. Biomedicine & Pharmacotherapy, 63, 86–94.Google Scholar
  124. Singh, N., Nigam, M., Ranjan, V., et al. (2009). Caspase mediated enhanced apoptotic action of cyclophosphamide- and resveratrol-treated MCF-7 cells. Journal of Pharmacological Sciences, 109, 473–485.PubMedGoogle Scholar
  125. Singh, U. P., Singh, N. P., Singh, B., et al. (2010). Resveratrol (trans-3,5,4′-trihydroxystilbene) induces silent mating type information regulation-1 and down-regulates nuclear transcription factor-κb activation to abrogate dextran sulfate sodium-induced colitis. The Journal of Pharmacology and Experimental Therapeutics, 332, 829–839.PubMedGoogle Scholar
  126. Smith, P. G., Wang, F., Wilkinson, K. N., et al. (2005). The phosphodiesterase PDE4B limits cAMP-associated PI3K/AKT-dependent apoptosis in diffuse large B-cell lymphoma. Blood, 105, 308–316.PubMedGoogle Scholar
  127. Stearns, M. E., Kim, G., Garcia, F., et al. (2004). Interleukin-10 induced activating transcription factor 3 transcriptional suppression of matrix metalloproteinase-2 gene expression in human prostate CPTX-1532 cells. Molecular Cancer Research, 2, 403–416.PubMedGoogle Scholar
  128. Sun, C., Hu, Y., Liu, X., et al. (2006). Resveratrol downregulates the constitutional activation of nuclear factor-κB in multiple myeloma cells, leading to suppression of proliferation and invasion, arrest of cell cycle, induction of apoptosis. Cancer Genetics and Cytogenetics, 165, 9–19.PubMedGoogle Scholar
  129. Sun, J., Watkins, G., Blair, A. L., et al. (2008). Deregulation of cofactor of BRCA1 expression in breast cancer cells. Journal of Cellular Biochemistry, 103, 1798–1807.PubMedGoogle Scholar
  130. Surh, Y. J. (2003). Cancer chemoprevention with dietary phytochemicals. Nature Reviews Cancer, 3, 768–780.PubMedGoogle Scholar
  131. Szaefer, H., Krajka-Kuzniak, V., & Baer-Dubowska, W. (2008). The effect of initiating doses of benzo[a]pyrene and 7,12-dimethylbenz[a]anthracene on the expression of PAH activating enzymes and its modulation by plant phenols. Toxicology, 251, 28–34.PubMedGoogle Scholar
  132. Tang, F. Y., Chiang, E. P., & Sun, Y. C. (2008a). Resveratrol inhibits heregulin-β1-mediated matrix metalloproteinase-9 expression and cell invasion in human breast cancer cells. The Journal of Nutritional Biochemistry, 19, 287–294.Google Scholar
  133. Tang, F. Y., Su, Y. C., Chen, N. C., et al. (2008b). Resveratrol inhibits migration and invasion of human breast-cancer cells. Molecular Nutrition & Food Research, 52, 683–691.Google Scholar
  134. Teh, M. T., Blaydon, D., Ghali, L. R., et al. (2007). Role for WNT16B in human epidermal keratinocyte proliferation and differentiation. Journal of Cell Science, 120, 330–339.PubMedGoogle Scholar
  135. Turchi, L., Aberdam, E., Mazure, N., et al. (2008). Hif-2alpha mediates UV-induced apoptosis through a novel ATF3-dependent death pathway. Cell Death and Differentiation, 15, 1472–1480.PubMedGoogle Scholar
  136. Um, H., Bae, J., Park, J., et al. (2010). Differential effects of resveratrol and novel resveratrol derivative, HS-1793, on endoplasmic reticulum stress-mediated apoptosis and Akt inactivation. International Journal of Oncology, 36, 1007–1013.PubMedGoogle Scholar
  137. Upadhyay, G., Singh, A. K., Kumar, A., et al. (2008). Resveratrol modulates pyrogallol-induced changes in hepatic toxicity markers, xenobiotic metabolizing enzymes and oxidative stress. European Journal of Pharmacology, 596, 146–152.PubMedGoogle Scholar
  138. Vanamala, J., Reddivari, L., Radhakrishnan, S., et al. (2010). Resveratrol suppresses IGF-1 induced human colon cancer cell proliferation and elevates apoptosis via suppression of IGF-1R/Wnt and activation of p53 signaling pathways. BMC Cancer, 10, 238.PubMedGoogle Scholar
  139. van de Weerdt, B. C., & Medema, R. H. (2006). Polo-like kinases: A team in control of the division. Cell Cycle, 5, 853–864.PubMedGoogle Scholar
  140. Vermeulen, K., Van Bockstaele, D. R., & Berneman, Z. N. (2003). The cell cycle: A review of regulation, deregulation and therapeutic targets in cancer. Cell Proliferation, 36, 131–149.PubMedGoogle Scholar
  141. Wang, Q., Mora-Jensen, H., Weniger, M. A., et al. (2009). ERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3-only protein NOXA in cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 106, 2200–2205.PubMedGoogle Scholar
  142. Wang, R. H., Zheng, Y., Kim, H. S., et al. (2008). Interplay among BRCA1, SIRT1, survivin during BRCA1-associated tumorigenesis. Molecular Cell, 32, 11–20.PubMedGoogle Scholar
  143. Wattenberg, L. W. (1996). Chemoprophylaxis of carcinogenesis: A review. Cancer Research, 26(7 Part 1), 1520–1526.Google Scholar
  144. Whitlock, N. C., Bahn, J. H., Lee, S. H., et al. (2011). Resveratrol-induced apoptosis is mediated by early growth response-1, Kruppel-like factor 4, and activating transcription factor 3. Cancer Prevention Research, 4, 116–127.PubMedGoogle Scholar
  145. Wilson, L. C., Baek, S. J., Call, A., et al. (2003). Nonsteroidal anti-inflammatory drug-activated gene (NAG-1) is induced by genistein through the expression of p53 in colorectal cancer cells. International Journal of Cancer, 105, 747–753.Google Scholar
  146. Wolter, F., Akoglu, B., Clausnitzer, A., et al. (2001). Downregulation of the cyclin D1/cdk4 complex occurs during resveratrol-induced cell cycle arrest in colon cancer cell lines. The Journal of Nutrition, 131, 2197–2203.PubMedGoogle Scholar
  147. Woo, K. J., Lee, T. J., Lee, S. H., et al. (2007). Elevated gadd153/chop expression during resveratrol-induced apoptosis in human colon cancer cells. Biochemical Pharmacology, 73, 68–76.PubMedGoogle Scholar
  148. Wu, Y., & Zhou, B. (2009). Inflammation: A driving force speed cancer metastasis. Cell Cycle, 8, 3267–3273.PubMedGoogle Scholar
  149. Wu, Y., & Zhou, B. P. (2010). TNF-α/NF-κB/Snail pathway in cancer cell migration and invasion. British Journal of Cancer, 102, 639–644.PubMedGoogle Scholar
  150. Yamaguchi, K., Lee, S. H., Kim, J. S., et al. (2006). Activating transcription factor 3 and early growth response 1 are the novel targets of LY294002 in a phosphatidylinositol 3-kinase--independent pathway. Cancer Research, 66, 2376–2384.PubMedGoogle Scholar
  151. Yan, C., & Boyd, D. D. (2006). ATF3 regulates the stability of p53: A link to cancer. Cell Cycle, 5, 926–929.PubMedGoogle Scholar
  152. Yan, C., Wang, H., & Boyd, D. D. (2002). ATF3 represses 72-kDa type IV collagenase (MMP-2) expression by antagonizing p53-dependent trans-activation of the collagenase promoter. The Journal of Biological Chemistry, 277, 10804–10812.PubMedGoogle Scholar
  153. Yan, C., Jamaluddin, M. S., Aggarwal, B., et al. (2005). Gene expression profiling identifies activating transcription factor 3 as a novel contributor to the proapoptotic effect of curcumin. Molecular Cancer Therapeutics, 4, 233–241.PubMedGoogle Scholar
  154. Yin, X., DeWille, J. W., & Hai, T.(2007). A potential dichotomous role of ATF3, an adaptive-response gene, in cancer development. Oncogene, 27, 2118–2127.PubMedGoogle Scholar
  155. Yu, H., Pan, C., Zhao, S., et al. (2008). Resveratrol inhibits tumor necrosis factor-[alpha]-mediated matrix metalloproteinase-9 expression and invasion of human hepatocellular carcinoma cells. Biomedicine & Pharmacotherapy, 62, 366–372.Google Scholar
  156. Zahid, M., Gaikwad, N. W., Ali, M. F., et al. (2008). Prevention of estrogen-DNA adduct formation in MCF-10F cells by resveratrol. Cancer Prevention Research, 45, 136–145.Google Scholar
  157. Zetter, P., & Bruce, R. (1998). Angiogenesis and tumor metastasis. Annual Review of Medicine, 49, 407–424.PubMedGoogle Scholar
  158. Zhang, H., Shih, A, Rinna, A., et al. (2010). Exacerbation of tobacco smoke mediated apoptosis by resveratrol: An unexpected consequence of its antioxidant action. The International Journal of Biochemistry & Cell Biology. doi:10.1016/j.biocel.2009.12.022.Google Scholar
  159. Zhang, Q., Tang, X., Lu, Q. Y., et al. (2005). Resveratrol inhibits hypoxia-induced accumulation of hypoxia-inducible factor-1α and VEGF expression in human tongue squamous cell carcinoma and hepatoma cells. Molecular Cancer Therapeutics, 4, 1465–1474.PubMedGoogle Scholar
  160. Zykova, T. A., Zhu, F., Zhai, X., et al. (2008). Resveratrol directly targets COX-2 to inhibit carcinogenesis. Molecular Carcinogenesis, 47, 797–805.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2011

Authors and Affiliations

  1. 1.Department of Pathobiology, College of Veterinary MedicineUniversity of TennesseeKnoxvilleUSA
  2. 2.Laboratory of Environmental Carcinogenesis, Department of Pathobiology, College of Veterinary MedicineUniversity of TennesseeKnoxvilleUSA

Personalised recommendations